Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

PharmaNeuroBoost N.V.165 enrolled

Overview

The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients. Secondary objectives are to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD: 1. Will increase the rate of resolution of symptoms with citalopram 40 mg. 2. Show the combined product to be safe and tolerable. Patients are scheduled to receive study medication for eight weeks and a final follow-up check will be carried out 28 days after completing the study. All patients will receive active citalopram from baseline and will be randomised to receive either active pipamperone or a placebo equivalent for eight weeks during which time they will attend for 6 study visits.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

165

Conditions

Depression

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients * 18-65 years inclusive * Suffering from a moderate to severe MDD as defined by DSM IV with an existence of depressed mood and loss of interest/anhedonia for at least four weeks and no longer than six months for the current episode * Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0. * Clinical global impression - severity scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline * A non-psychotic state * Where appropriate, male patients should agree to use barrier contraceptive measures (condoms) during the course of the study and for three months after the last dose of medication Exclusion Criteria: * Premenopausal females not using adequate contraceptive measures * Considered by the investigator to be a significant risk of suicide or scoring 5 or more on the MADRS question 10 * Significant other psychiatric illness which would interfere with trial assessments - co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis * Significant physical illness which would interfere with trial assessments * Reduced hepatic function * Epilepsy * History of cardiac dysrhythmia * Alcohol intake above accepted UK ranges * Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion including lithium or other mood stabilisers * Resistant depression defined as having failed to respond to * Two previous antidepressants at an adequate dose ingested for at least 4 weeks during the current episode * To an augmentation therapy with an atypical antipsychotic drug * Electroconvulsive therapy (ECT) for the current episode * Formal psychotherapy or alternative treatments for one week prior to or during the study

Outcomes

Primary Outcomes

Change in Montgomery-Asberg Depression Rating Scale score

Time frame: 8 weeks

Secondary Outcomes

The number of patients showing evidence of onset of action defined as a 20% improvement from baseline MADRS

Time frame: At Weeks 1 and 2